ArticleAntibiotics (Basel, Switzerland)2026
Physicochemical Stability of Aztreonam/Avibactam in Elastomeric Devices for Outpatient Parenteral Antimicrobial Therapy.
Article in Antibiotics (Basel, Switzerland), 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
9 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
BACKGROUND/
objectivesOutpatient Parenteral Antimicrobial Therapy (OPAT) programs provide a safe and cost-effective strategy for administering intravenous antimicrobials in the home setting. Aztreonam/avibactam (ATM/AVI) is a reserve antibiotic used to treat infections caused by multidrug-resistant Gram-negative bacteria. The aim of this study was to evaluate the physicochemical stability of ATM/AVI in elastomeric pumps for OPAT use.
methodsATM/AVI was diluted in a 0.9% sodium chloride solution to a concentration of 25/8.33 mg/mL and stored in elastomeric pumps (Infusor LV 10 mL/h, 240 mL; Baxter Healthcare S.A, Zurich, Switzerland). The devices were maintained at 4 °C for 14 days and at 25, 32, and 37 °C for 48 h. Three independent elastomeric devices were prepared for each temperature condition and sampled in duplicate at each time point. Solutions were considered stable if the color, clarity, and pH remained unchanged and if the percentage of intact drug remained ≥90%, as determined via UHPLC-MS/MS.
resultsATM/AVI in polyisoprene elastomeric devices remained physicochemically stable for up to 14 days under refrigerated conditions and for 48 h at 25 °C, 32 °C, and 37 °C.
conclusionsATM/AVI solutions demonstrated prolonged stability under the evaluated conditions, supporting their potential use in OPAT programs via 24 h continuous infusion.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.